AVITA Medical, Inc.
RCELNASDAQHealthcare● Active
$4.21
+$0.05(+1.20%)
Market Cap$104588609
P/E Ratio—
52W High$7.12
52W Low$3.22
AVITA Medical, Inc. (RCEL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RCEL · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.35
Est. -$0.35 · +0.0%
Revenue
$0.02B
Est. $0.02B · +5.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
RCEL reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.32 | — | — | — | $0.02B | — |
| — Q2 FY2026 | May 14, 2026 | -$0.35 | -$0.35 | +0.0% | $0.02B | $0.02B | +5.2% |
| ▼ Q1 FY2026 | Feb 12, 2026 | -$0.36 | -$0.38 | -4.3% | $0.02B | $0.02B | -2.3% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.43 | -$0.46 | -7.0% | $0.02B | $0.03B | -36.5% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.26 | -$0.38 | -46.1% | $0.01B | $0.04B | -70.1% |
| ▼ Q2 FY2025 | May 8, 2025 | -$0.39 | -$0.53 | -35.9% | $0.01B | $0.04B | -68.9% |
| ▼ Q1 FY2025 | Feb 13, 2025 | -$0.30 | -$0.44 | -46.7% | $0.01B | $0.03B | -63.9% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.42 | -$0.62 | -47.6% | $0.01B | $0.04B | -61.8% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.32
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026
EPS Actual
-$0.35
EPS Est.
-$0.35
EPS Surpr.
+0.0%
Revenue
$0.02B
Q1 FY2026
Feb 12, 2026Miss
EPS Actual
-$0.38
EPS Est.
-$0.36
EPS Surpr.
-4.3%
Revenue
$0.02B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.46
EPS Est.
-$0.43
EPS Surpr.
-7.0%
Revenue
$0.02B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.38
EPS Est.
-$0.26
EPS Surpr.
-46.1%
Revenue
$0.01B
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$0.53
EPS Est.
-$0.39
EPS Surpr.
-35.9%
Revenue
$0.01B
Q1 FY2025
Feb 13, 2025Miss
EPS Actual
-$0.44
EPS Est.
-$0.30
EPS Surpr.
-46.7%
Revenue
$0.01B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.62
EPS Est.
-$0.42
EPS Surpr.
-47.6%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.09 | $-0.09 | $-0.09 | 1 |
| Q3 FY2028 | $-0.14 | $-0.14 | $-0.13 | 1 |
| Q2 FY2028 | $-0.16 | $-0.15 | $-0.15 | 1 |
| Q1 FY2028 | $-0.16 | $-0.15 | $-0.15 | 1 |
| Q4 FY2027 | $-0.27 | $-0.26 | $-0.24 | 1 |
| Q3 FY2027 | $-0.29 | $-0.28 | $-0.27 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 14, 2026 | +0.0% | $4.26 | $4.36 | +2.35% |
| ▼ Q1 FY2026 | Feb 12, 2026 | -4.3% | $3.84 | $3.72 | -3.12% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -7.0% | $3.50 | $3.40 | -2.86% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -46.1% | $5.36 | $5.38 | +0.37% |
| ▼ Q2 FY2025 | May 8, 2025 | -35.9% | $9.47 | $9.33 | -1.48% |
| ▼ Q1 FY2025 | Feb 13, 2025 | -46.7% | $8.61 | $8.78 | +1.97% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -47.6% | $12.19 | $12.40 | +1.72% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -1.7% | $8.00 | $7.93 | -0.88% |
Q2 FY2026+2.35%
Report Date
May 14, 2026
EPS Beat/Miss
+0.0%
Price Before
$4.26
Price After
$4.36
Q1 FY2026-3.12%
Report Date
Feb 12, 2026
EPS Beat/Miss
-4.3%
Price Before
$3.84
Price After
$3.72
Q4 FY2025-2.86%
Report Date
Nov 6, 2025
EPS Beat/Miss
-7.0%
Price Before
$3.50
Price After
$3.40
Q3 FY2025+0.37%
Report Date
Aug 7, 2025
EPS Beat/Miss
-46.1%
Price Before
$5.36
Price After
$5.38
Q2 FY2025-1.48%
Report Date
May 8, 2025
EPS Beat/Miss
-35.9%
Price Before
$9.47
Price After
$9.33
Q1 FY2025+1.97%
Report Date
Feb 13, 2025
EPS Beat/Miss
-46.7%
Price Before
$8.61
Price After
$8.78
Q4 FY2024+1.72%
Report Date
Nov 7, 2024
EPS Beat/Miss
-47.6%
Price Before
$12.19
Price After
$12.40
Q3 FY2024-0.88%
Report Date
Aug 8, 2024
EPS Beat/Miss
-1.7%
Price Before
$8.00
Price After
$7.93
Avg Beat Reaction+2.35%
Avg Miss Reaction-0.61%
Beat Rate1 / 8 quarters
Largest Move-3.12% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RCEL ends December
AVITA Medical, Inc. (RCEL) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.35 (in line with the analyst consensus of $-0.35). The next RCEL earnings date is expected around September 1, 2026.
Each quarter, investors track RCEL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RCEL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RCEL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RCEL earnings · 4 questionsAVITA Medical, Inc.'s next earnings report is expected around September 1, 2026. RCEL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RCEL historically reports after market close (AMC).
RCEL earnings datewhen is RCEL earningsRCEL next earnings datewhen does RCEL report earningsRCEL earnings calendar
▸ Source: FMP · AVITA Medical, Inc. SEC filings · US GAAP · AVITA Medical, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026